Manufacturer of small molecule innovator and generic active pharmaceutical ingredients (APIs), Cambrex, has completed its acquisition of dosage form contract development and manufacturing organisation (CDMO), Halo Pharma.
Acquisition
The transaction, which was initially announced in July this year (2018), has completed for approximately $425 million and will see the addition of formulation development and finished dosage manufacturing capabilities to Cambrex’s existing global API manufacturing network.
“The acquisition is well-aligned with our commitment to providing best-in-class services to meet the needs of our global pharmaceutical, biotech and generic customers and the combined business creates a leading small molecule CDMO with both API and finished dosage development and manufacturing capabilities,” commented Steve Klosk, president and CEO of Cambrex.
“This acquisition expands our manufacturing footprint with the addition of two state-of-the art, GMP compliant manufacturing facilities in North America, both with a strong reputation for quality and excellent track records with regulatory approvals from the US FDA, EMEA, DEA and Health Canada,” added Shawn Cavanagh, COO of Cambrex. “We look forward to welcoming the 450-person workforce in joining our existing 1,200 experts across the United States and Europe and to continue to build long-term partnerships with our customers.”